Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Haemostatic safety of a unique recombinant plasmin molecule lacking kringles 2-5.

Marder VJ, Manyak S, Gruber T, Goyal A, Moreno G, Hunt J, Bromirski J, Scuderi P, Petteway SR Jr, Novokhatny V.

Thromb Haemost. 2010 Oct;104(4):780-7. doi: 10.1160/TH09-10-0742. Epub 2010 Aug 30.

PMID:
20806125
2.

Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth.

Chen H, Gordon MS, Campbell RA, Li M, Wang CS, Lee HJ, Sanchez E, Manyak SJ, Gui D, Shalitin D, Said J, Chang Y, Deuel TF, Baritaki S, Bonavida B, Berenson JR.

Blood. 2007 Jul 1;110(1):287-95. Epub 2007 Mar 16.

3.

LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma.

Campbell RA, Manyak SJ, Yang HH, Sjak-Shie NN, Chen H, Gui D, Popoviciu L, Wang C, Gordon M, Pang S, Bonavida B, Said J, Berenson JR.

Int J Oncol. 2006 Jun;28(6):1409-17.

PMID:
16685443
4.

Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status.

Yeh HS, Chen H, Manyak SJ, Swift RA, Campbell RA, Wang C, Li M, Lee HJ, Waterman G, Gordon MS, Ma J, Bonavida B, Berenson JR.

Br J Haematol. 2006 Jun;133(5):526-9.

PMID:
16681640
5.

The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adams J, Sjak-Shie N, Vescio RA, Berenson JR.

Clin Cancer Res. 2003 Mar;9(3):1136-44.

6.

Identification of polymorphisms of the IkappaBalpha gene associated with an increased risk of multiple myeloma.

Parker KM, Ma MH, Manyak S, Altamirano CV, Tang YM, Frantzen M, Mikail A, Roussos E, Sjak-Shie N, Vescio RA, Berenson JR.

Cancer Genet Cytogenet. 2002 Aug;137(1):43-8.

PMID:
12377412

Supplemental Content

Loading ...
Support Center